ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

November 29, 2013

Pharmacia Letter Announces Suspension Of Two Trials.

May 11, 2001

NCI Official Says He Hopes to “Put More Money” Into SPOREs.

April 14, 2006

12 Minority CCOPs Awardees Names, San Antonio Gets 2

September 21, 1990

Study Links Exercise and Survival In Breast and Colon Cancer Mortality

May 25, 2012

DCPC Advisors Okay New Grant Programs To Improve Participation Of Women, Minorities In Clinical Trials

May 26, 1995